You are here: Industry Insights > Purdue Pharma

News List

J&J ends sales of opioids in the US, reaches settlement deal with New York firstwordpharma
June 28, 2021
Johnson & Johnson disclosed alongside a settlement agreement with the State of New York that it stopped selling prescription pain medicines in the US last year, having ceased marketing of the products in 2015.
Purdue Pharma pleads guilty to three criminal charges pharmaceutical-technology
November 26, 2020
Opioid maker Purdue Pharma has pleaded guilty in federal court in Newark, New Jersey, to criminal charges over the handling of its OxyContin painkiller drug.
Purdue Pharma reaches agreement with DOJ over opioid medicines pharmaceutical-technology
October 23, 2020
Purdue Pharma has reached an $8.3bn settlement agreement with the United States Department of Justice (DOJ) to resolve multi-year civil and criminal investigations into its past marketing practices related to its opioid medicines.
DOJ Announces Deal with Purdue Pharma, Civil Settlement with Sackler Family americanpharmaceuticalreview
October 22, 2020
The Department of Justice (DOJ) has announced a global resolution of its criminal and civil investigations into the opioid manufacturer Purdue Pharma, and a civil resolution of its civil investigation into individual shareholders from the Sackler family.
US seeks nearly $13bn from Purdue Pharma over opioid claims pharmaceutical-technology
August 07, 2020
The US Department of Justice is seeking approximately $13bn in criminal and civil penalties from Purdue Pharma over opioid claims filed against the company.
Eisai acquires rights to lemborexant from Purdue Pharma pharmaceutical-technology
May 05, 2019
Eisai has bought the rights to investigational drug lemborexant from Purdue Pharma, ending a global development and commercialisation alliance signed in 2015.
Under-fire Purdue hunts for ad agency to promote upcoming product: report fiercepharma
April 10, 2019
Purdue Pharma's opioid marketing days are over, but now, the company is reportedly looking for an ad agency to help promote a new product.
Purdue Pharma taps TetraGenetics for ion channel-focused pain treatments in $273M discovery pact fiercebiotech
February 27, 2019
Purdue Pharma’s newly formed clinical research subsidiary, Imbrium Therapeutics, has tapped TetraGenetics and its antibody discovery platform to help it develop new, non-opioid-based biologics for treating chronic pain....
Sackler family directed—and covered up—Purdue's opioid sales tactics. Now, it should pay the price: AG fiercepharma
January 17, 2019
Purdue Pharma has faced years of investigations and legal proceedings over its marketing for OxyContin. Now, Massachusetts Attorney General Maura Healey has filed an amended complaint laying out a detailed account of the alleged role the company's foundin
Eisai and Purdue Pharma seek US approval for lemborexant to treat insomnia pharmaceutical-technology
January 17, 2019
Eisai and its partner Purdue Pharma have submitted new drug application to the US Food and Drug Administration (FDA) seeking approval for lemborexant to treat insomnia, a sleep disorder.....

Previous page 1 2 Next page